Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Declines By 15.1%

Hypera S.A. (OTCMKTS:HYPMYGet Rating) was the recipient of a significant decline in short interest in the month of May. As of May 31st, there was short interest totalling 4,500 shares, a decline of 15.1% from the May 15th total of 5,300 shares. Based on an average daily trading volume, of 31,900 shares, the short-interest ratio is currently 0.1 days.

OTCMKTS HYPMY traded down $0.26 during trading on Friday, reaching $7.36. The company’s stock had a trading volume of 2,625 shares, compared to its average volume of 11,346. The stock has a market capitalization of $4.66 billion, a PE ratio of 17.52 and a beta of 0.73. Hypera has a 1-year low of $4.63 and a 1-year high of $8.89. The business has a 50-day moving average price of $7.89 and a 200-day moving average price of $6.63.

Hypera Company Profile (Get Rating)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.